Licensing · Türkiye · Announced 8 Oct 2026
Accord Healthcare → Centurion
Biosimilars extend a 2025 oncology collaboration, so this is two established partners deepening their portfolio. That's a stronger signal than a first deal.
Parties: Accord Healthcare Ltd (United Kingdom) → Centurion İlaç Sanayi ve Ticaret A.Ş. (Turkey)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- Türkiye
- Therapeutic area
- Immunology / Inflammation
- Asset
- Biosimilar product(s) — specific molecules not named in the announcement
- Announced
- 8 Oct 2026
Our analysis
It’s the second, deeper step in an existing relationship : Centurion and Accord signed a strategic oncology/biotech collaboration in March 2025 (to bring Accord’s advanced treatments to Türkiye)
This 2026 deal extends that into biosimilars specifically — so it’s a portfolio deepening between established partners, which is a stronger strategic signal than a cold first deal. That framing is the non-obvious point most coverage will miss
Who Accord really is — the India/Intas engine behind the “UK” label
Accord presents as UK-headquartered, but it is the international commercial vehicle of Intas Pharmaceuticals , one of India’s largest pharma groups (~21,000 staff; 10,000+ products across 85+ countries). Its biosimilar capability sits in Intas Biopharmaceuticals / Accord BioPharma , with a portfolio spanning pegfilgrastim, filgrastim, trastuzumab, ustekinumab, denosumab and (newly) golimumab biosimilars. So for your tracker this is effectively an India (Intas)-origin biosimilar portfolio reaching Türkiye via a UK commercial brand — not a British-origin deal. Getting that provenance right is the key correction.
The full analysis is free to read with a work email on this page.
Source: Centurion Announcement